179.3K XNAS Volume
XNAS 28 Mar, 2025 5:30 PM (EDT)
Board Meeting
The board meeting for Eledon Pharmaceuticals Inc is scheduled for today, for the purpose of Eledon Pharmaceuticals Inc Fourth Quarter Earnings Results for 2024
See details
Eledon Pharmaceuticals Inc Key Metrics
Default
Market Capitalization | 200.6 |
PE TTM | -5.5 |
PEG TTM | -0.1 |
Price to Book | 2.6 |
Institutional holding current Qtr % | 62.5 |
Net Profit Qtr Growth YoY % | -48.2 |
Net Profit TTM Growth % | 69 |
Rel Perf vs Sector quarter% | -27.4 |
All financials are in USD Million and price data in USD
VIEW MORE
Not Eligible
Expensive Valuation
Technically Neutral
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
8Positive9Negative
47.1% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Eledon Pharmaceuticals Inc Stock Price Analysis
Day Price Range | 3.4 (LTP) 3.33.4 LowHigh |
Week Price Range | 3.4 (LTP) 3.23.7 LowHigh |
Month Price Range | 3.4 (LTP) 3.24.3 LowHigh |
52 Week Price Range | 3.4 (LTP) 1.55.4 LowHigh |
Eledon Pharmaceuticals Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Eledon Pharmaceuticals Inc Stock Analysis
Eledon Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.
Eledon Pharmaceuticals Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Net Profit | $36.18 M | 68.95% | positive |
| |
Price to Earning Ratio | -5.54 | - | negative |
| |
Stock Price | $3.35 | 57.28% | positive |
| |
Quarterly Net profit | $44.62 M | 48.23% | negative |
| |
Mutual Fund Holding | 10.85 % | 2.28% | positive |
| |
Promoter Share Holding | 0.20 % | 0% | neutral |
| |
Institutional Holding | 62.48 % | 31.52% | positive |
|
Loading data..
Eledon Pharmaceuticals Inc - Company Profile
What does Eledon Pharmaceuticals Inc do?
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Eledon Pharmaceuticals Inc Management structure
All Gross Remunerations are in USD
Eledon Pharmaceuticals Inc Board of directors
All Gross Remunerations are in USD